Warner-Lambert v Actavis: day one from the UK Supreme Court

LSIPR attended a packed UK Supreme Court yesterday for day one of a four-day hearing, with Warner-Lambert debating the role that plausibility plays in patent law. Below we provide an overview of the case and its core issues.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

The curtain closes on three major drug disputes

11 February 2026 Courts on both sides of the Atlantic recorded a flurry of settlements this week, as Astellas, GSK, and Alexion drew a line under long-running disputes with generic rivals.

Big Pharma

The clinical trial dilemma: Navigating European practice

27 November 2025 Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.

Big Pharma

Report reveals surge of AI adoption in IP but lawyers remain cautious

20 November 2025 A new report from Clarivate highlights a jump in the tech’s adoption among IP professionals over the past two years, as well as concerns over governance.

More features

BioNTech fires shots at Moderna's next-generation vaccine

Mintz gains ex-Winston & Strawn partner and ITC expert

Abbott unit defends European protection for heart valve ‘cuff’ design

Natera targets ex-employee over mass file download before rival move

Hogan Lovells makes senior public and administrative hire in Italy

Danaher moves to acquire Masimo in $9.9bn deal

Generic rival blocked as AZ defends diabetes stronghold

Emotional Perception exclusive: ‘We are now very much open for business’

Warner-Lambert v Actavis: day one from the UK Supreme Court

More on this story

Editor's picks

Editor's picks

More features